FASLODEX (fulvestrant)
ANTIESTROGEN·HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL ADVANCED BREAST CANCER·+1
AstraZeneca Pharmaceuticals
Indication
Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer
Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer is an invasive malignancy originating in the female mammary epithelium that has progressed to locally advanced, unresectable disease or distant metastases (Stage III–IV). Read more about Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer
24 drugs 24 manufacturers
Drugs that treat it
Common Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer therapies.
FULVESTRANT
ANTIESTROGEN·HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL ADVANCED BREAST CANCER·+1
SANDOZ
FULVESTRANT
ANTIESTROGEN·HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL ADVANCED BREAST CANCER·+1
GLENMARK PHARMA
FULVESTRANT
ANTIESTROGEN·HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL ADVANCED BREAST CANCER·+1
SAGENT PHARMACE
FULVESTRANT
HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL ADVANCED BREAST CANCER·+1
MYLAN INSTITUTI
FULVESTRANT
HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL ADVANCED BREAST CANCER·+1
ASTRAZENECA LP/
FULVESTRANT
ANTIESTROGEN·HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL ADVANCED BREAST CANCER·+1
AMNEAL BIOSCIEN
FULVESTRANT
ANTIESTROGEN·HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL ADVANCED BREAST CANCER·+1
FRESENIUS KABI
FULVESTRANT
HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL ADVANCED BREAST CANCER·+1
Actavis Pharma
Filter & compare in the drug finder →Opens the drug finder with Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHormone receptor (HR)-positive, HER2-negative advanced female breast cancer is an invasive malignancy originating in the female mammary epithelium that has progressed to locally advanced, unresectable disease or distant metastases (Stage III–IV).
Pathophysiologically, the tumor cells express estrogen receptors, progesterone receptors, or both, which drive oncogenic cell proliferation and survival in response to endocrine signaling.
Concurrently, these malignant cells do not overexpress human epidermal growth factor receptor 2 (HER2) protein or exhibit *ERBB2* gene amplification.
Although this subtype accounts for the majority of female breast cancer diagnoses and maintains a reliance on hormone-mediated pathways, advanced disease represents an aggressive, largely incurable systemic stage characterized by eventual therapeutic resistance and metastatic spread to sites such as bone, viscera, or distant lymph nodes.
- fda.gov
Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer is an invasive malignancy originating in the female mammary epithelium that has progressed to locally advanced, unresectable disease or distant metastases (Stage III–IV) Although this subtype accounts for the majority of female breast cancer diagnoses and maintains a reliance on hormone-mediated pathways, advanced disease represents an aggressive, largely incurable systemic stage characterized by eventual therapeutic res...
- clevelandclinic.org
Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer is an invasive malignancy originating in the female mammary epithelium that has progressed to locally advanced, unresectable disease or distant metastases (Stage III–IV) Pathophysiologically, the tumor cells express estrogen receptors, progesterone receptors, or both, which drive oncogenic cell proliferation and survival in response to endocrine signaling
- patientresource.com
Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer is an invasive malignancy originating in the female mammary epithelium that has progressed to locally advanced, unresectable disease or distant metastases (Stage III–IV) Although this subtype accounts for the majority of female breast cancer diagnoses and maintains a reliance on hormone-mediated pathways, advanced disease represents an aggressive, largely incurable systemic stage characterized by eventual therapeutic res...
- cancer.gov
Pathophysiologically, the tumor cells express estrogen receptors, progesterone receptors, or both, which drive oncogenic cell proliferation and survival in response to endocrine signaling
- mayoclinic.org
Concurrently, these malignant cells do not overexpress human epidermal growth factor receptor 2 (HER2) protein or exhibit *ERBB2* gene amplification
- stopbreastcancer.org
Although this subtype accounts for the majority of female breast cancer diagnoses and maintains a reliance on hormone-mediated pathways, advanced disease represents an aggressive, largely incurable systemic stage characterized by eventual therapeutic resistance and metastatic spread to sites such as bone, viscera, or distant lymph nodes
Personalize your experience
Follow Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.